TY - JOUR
T1 - Obesity-Related Glomerulopathy
T2 - Clinical Management
AU - Herman-Edelstein, Michal
AU - Weinstein, Talia
AU - Chagnac, Avry
N1 - Publisher Copyright:
© 2021
PY - 2021/7
Y1 - 2021/7
N2 - Obesity-related glomerulopathy (ORG) and other obesity-associated kidney diseases pose a major challenge to the treating nephrologist. We review the benefits of weight loss and optimal management of ORG and kidney disease in the setting of obesity. Therapeutic strategies in ORG were limited mainly in the past to weight loss through lifestyle interventions and bariatric surgery, antihypertensive treatment, and renin-angiotensin-aldosterone system blockade. Current approaches to obtain the desired weight loss include novel pharmacologic therapies that have been approved for the treatment of diabetes while offering kidney protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1–receptor agonists. This review focuses on the nephroprotective role of the renin-angiotensin-aldosterone system blockade and of these new pharmacologic agents, and on the renal effects of bariatric surgery in chronic kidney disease.
AB - Obesity-related glomerulopathy (ORG) and other obesity-associated kidney diseases pose a major challenge to the treating nephrologist. We review the benefits of weight loss and optimal management of ORG and kidney disease in the setting of obesity. Therapeutic strategies in ORG were limited mainly in the past to weight loss through lifestyle interventions and bariatric surgery, antihypertensive treatment, and renin-angiotensin-aldosterone system blockade. Current approaches to obtain the desired weight loss include novel pharmacologic therapies that have been approved for the treatment of diabetes while offering kidney protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1–receptor agonists. This review focuses on the nephroprotective role of the renin-angiotensin-aldosterone system blockade and of these new pharmacologic agents, and on the renal effects of bariatric surgery in chronic kidney disease.
KW - Obesity-related glomerulopathy
KW - obesity-associated kidney diseases
UR - http://www.scopus.com/inward/record.url?scp=85114316143&partnerID=8YFLogxK
U2 - 10.1016/j.semnephrol.2021.06.007
DO - 10.1016/j.semnephrol.2021.06.007
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 34715965
AN - SCOPUS:85114316143
SN - 0270-9295
VL - 41
SP - 358
EP - 370
JO - Seminars in Nephrology
JF - Seminars in Nephrology
IS - 4
ER -
